Drug development - August 16, 2013
Genovis evaluates new diagnosis technology
Genovis has signed an agreement with Respiratorius to evaluate a new technology for the early diagnosis of cardiovascular disease. The agreement involves tests and evaluation of RESP-3000 as a new biomarker for early diagnosis of cardiovascular disease using PET-imaging. The final evaluation will be conducted by GeccoDots AB, Genovis’ wholly owned subsidiary. According to a […]